Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
“Sirtinol, cambinol, and EX-527 are specific SIRT1 and SIRT2 inhibitors (Ceccacci and Minucci, 2016; Eckschlager et al., 2017).”
BackgroundThirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
“HDACi have pleiotropic cellular effects (Figure 2) and induce the expression of pro-apoptotic genes/proteins, cause cellular differentiation and/or cell cycle arrest (13, 15, 19, 25, 26).”
BackgroundToward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
A short guide to histone deacetylases including recent progress on class II enzymes
Park, S.-Y., & Kim, J.-S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0382-4 · Cited by 509
Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment
Yang, Q., Ciebiera, M., Bariani, M. V., Ali, M., Elkafas, H., Boyer, T. G., & Al-Hendy, A. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab039 · Cited by 425
Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., & Giorgi, F. M. (2020) · Genes · doi:10.3390/genes11050556 · Cited by 423
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium
Konkankit, C. C., Marker, S. C., Knopf, K. M., & Wilson, J. J. (2018) · Dalton Transactions · doi:10.1039/c8dt01858h · Cited by 284
Russo, S., Kwiatkowski, M., Govorukhina, N., Bischoff, R., & Melgert, B. N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.746151 · Cited by 269
Autophagy in the physiological endometrium and cancer
Devis-Jauregui, L., Eritja, N., Davis, M. L., Matias-Guiu, X., & Llobet-Navàs, D. (2021) · Autophagy · doi:10.1080/15548627.2020.1752548 · Cited by 222
“as potential therapeutic agents in cancer treatment [81], including EC [82].”
BackgroundTargeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
Singh, A. K., Bishayee, A., & Pandey, A. K. (2018) · Nutrients · doi:10.3390/nu10060731 · Cited by 221
“Ricolinostat DAC 6 , Ly pho a Phase I and II trial [115]”
BackgroundAl Bitar, S., & Gali-Muhtasib, H. (2019) · Cancers · doi:10.3390/cancers11101475 · Cited by 224
HDAC Inhibitors in Acute Myeloid Leukemia
San José-Enériz, E., Gimenez-Camino, N., Agirre, X., & Prosper, F. (2019) · Cancers · doi:10.3390/cancers11111794 · Cited by 222
“Valproic acid (VPA) is an inhibitor of class I and IIa HDACs that has shown antitumor effects [39,62].”
BackgroundImmunotherapy in Renal Cell Carcinoma: The Future Is Now
Deleuze, A., Saout, J., Dugay, F., Peyronnet, B., Mathieu, R., Verhoest, G., Bensalah, K., Crouzet, L., Laguerre, B., Belaud-Rotureau, M.-A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072532 · Cited by 198
“Histone deacetylase (HDAC) inhibitors modify the chromatin accessibility and play a crucial role in cycle arrest and apoptosis and could eventually enhance tumour antigens release and indirectly improve antigen presentation by APC and T cells priming [67].”
BackgroundHuwiler, A., & Zangemeister-Wittke, U. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.001 · Cited by 221
“…acetyltransferases (HAT) and associates with active gene transcription because acetylation of histones loosens the contact between core nucleosome proteins and DNA and facilitates the binding of transcription factors to their respective binding sites (Eckschlager et al., 2017; Kelly et al., 2013).”
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Neutrophils as potential therapeutic targets in hepatocellular carcinoma
Geh, D., Leslie, J., Rumney, R., Reeves, H. L., Bird, T. G., & Mann, D. A. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00568-5 · Cited by 218
Trends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 208
“HDACs are considered as potential anticancer drugs with multimodal properties [276] including potent angiogenesis inhibitor activity which alters VEGF signaling [277].”
BackgroundEffects of Intestinal Microbial–Elaborated Butyrate on Oncogenic Signaling Pathways
Chen, J., Zhao, K.-N., & Vitetta, L. (2019) · Nutrients · doi:10.3390/nu11051026 · Cited by 198
Shu, F., Xiao, H., Li, Q.-N., Ren, X.-S., Liu, Z.-G., Hu, B.-W., Wang, H.-S., Wang, H., & Jiang, G.-M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01300-8 · Cited by 192
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197
Jenke, R., Reßing, N., Hansen, F. K., Aigner, A., & Büch, T. (2021) · Cancers · doi:10.3390/cancers13040634 · Cited by 180
Ghafouri-Fard, S., Abak, A., Tondro Anamag, F., Shoorei, H., Fattahi, F., Javadinia, S. A., Basiri, A., & Taheri, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658636 · Cited by 193
Biohorology and biomarkers of aging: Current state-of-the-art, challenges and opportunities
Galkin, F., Mamoshina, P., Aliper, A., de Magalhães, J. P., Gladyshev, V. N., & Zhavoronkov, A. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101050 · Cited by 189
Histone acetylation and the role of histone deacetylases in normal cyclic endometrium
Gujral, P., Mahajan, V., Lissaman, A. C., & Ponnampalam, A. P. (2020) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-020-00637-5 · Cited by 191
Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
Hontecillas-Prieto, L., Flores-Campos, R., Silver, A., de Álava, E., Hajji, N., & García-Domínguez, D. J. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.578011 · Cited by 177
Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets
Bajbouj, K., Al-Ali, A., Ramakrishnan, R. K., Saber-Ayad, M., & Hamid, Q. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111701 · Cited by 176
“HDAC inhibition causes acetylation not only of histones but also transcription factors such as p53, GATA-1, and estrogen receptor-alpha [64].”
BackgroundThe many lives of KATs — detectors, integrators and modulators of the cellular environment
Sheikh, B. N., & Akhtar, A. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0072-4 · Cited by 172
Targeting epigenetics for cancer therapy
Park, J. W., & Han, J.-W. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01126-z · Cited by 166
Oh, J. M., & Ahn, B.-C. (2021) · Theranostics · doi:10.7150/thno.57689 · Cited by 163
“HDAC inhibitors are classified based on their specificity as members of five classes of compounds: (1) hydroxamic acids (hydroxamates), (2) short chain fatty (aliphatic) acids, (3) benzamides, (4) cyclic tetrapeptides, and (5) sirtuin inhibitors such as the pan-inhibitor nicotinamide and the specific SIRT1 and SIRT2 i…”
BackgroundKabakov, A. E., & Yakimova, A. O. (2021) · Cancers · doi:10.3390/cancers13051102 · Cited by 180
The Role of Isothiocyanates as Cancer Chemo-Preventive, Chemo-Therapeutic and Anti-Melanoma Agents
Mitsiogianni, M., Koutsidis, G., Mavroudis, N., Trafalis, D. T., Botaitis, S., Franco, R., Zoumpourlis, V., Amery, T., Galanis, Α., Pappa, A., et al. (2019) · Antioxidants · doi:10.3390/antiox8040106 · Cited by 170
“To date, HDAC inhibitors have been utilized in the clinical setting and are considered to be therapeutic agents against tumour progression by causing cell cycle arrest, inducing cell death and inhibiting angiogenesis [177,178].”
MethodActivity-Based Fluorescence Diagnostics for Cancer
Fujita, K., & Urano, Y. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00612 · Cited by 164
Genetic and Epigenetic Aspects of Atopic Dermatitis
Nedoszytko, B., Reszka, E., Gutowska‐Owsiak, D., Trzeciak, M., Lange, M., Jarczak, J., Niedoszytko, M., Jabłońska, E., Romantowski, J., Strapagiel, D., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186484 · Cited by 190
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives
Wołącewicz, M., Hrynkiewicz, R., Grywalska, E., Suchojad, T., Leksowski, T., Roliński, J., & Niedźwiedzka‐Rystwej, P. (2020) · Cancers · doi:10.3390/cancers12051181 · Cited by 163
Soltan, O. M., Shoman, M. E., Abdel‐Aziz, S. A., Narumi, A., Konno, H., & Abdel‐Aziz, M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113768 · Cited by 157
Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
Verza, F. A., Das, U., Fachin, A. L., Dimmock, J. R., & Marins, M. (2020) · Cancers · doi:10.3390/cancers12061664 · Cited by 143
“These compounds are classified into two large classes, isoform-selective inhibitors and pan-inhibitors, which act against all class I HDACs [134,190].”
BackgroundNext-generation of selective histone deacetylase inhibitors
Yang, F., Zhao, N., Ge, D., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra02985k · Cited by 157
Esteve, M. (2020) · Frontiers in Nutrition · doi:10.3389/fnut.2020.00111 · Cited by 154
“The overexpression of HDACs are a common hallmark of cancer and their inhibition is considered to be therapeutic against cancer tumor progression (162, 163).”
BackgroundThe emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 149
Antioxidant Metabolism Pathways in Vitamins, Polyphenols, and Selenium: Parallels and Divergences
Andrés, C. M. C., de la Lastra, J. M. P., Andrés, C., Plou, F. J., & Pérez‐Lebeña, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052600 · Cited by 159
“These inhibitors are being investigated as potential therapeutic agents for various diseases, including cancer, Alzheimer’s disease, and type 2 diabetes [262].”
BackgroundEpigenetic Regulations in Neuropsychiatric Disorders
Kuehner, J. N., Bruggeman, E. C., Wen, Z., & Yao, B. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00268 · Cited by 136
Xia, C., Tao, Y., Li, M., Che, T., & Qu, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9073 · Cited by 136
“In addition, a number of studies have demonstrated that KDACIs can inhibit cancer cells and reduce the resistance of cancer cells to other drugs, which makes it possible to use KDACIs in combination with other drugs to treat cancer (191).”
BackgroundImmunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 133
“Similarly, belinostat is part of the therapeutic regimen for peripheral T cell lymphoma while panobinostat has been studied in the setting of multiple myeloma (MM) [31].”
BackgroundInfluentialHistone Acetylation Promotes Neutrophil Extracellular Trap Formation
Hamam, H., Khan, M., & Palaniyar, N. (2019) · Biomolecules · doi:10.3390/biom9010032 · Cited by 131
Reversible, Spatial and Temporal Control over Protein Activity Using Light
Hoorens, M. W. H., & Szymański, W. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.05.004 · Cited by 147
STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment
Laudisi, F., Cherubini, F., Monteleone, G., & Stolfi, C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061787 · Cited by 127
“Currently, panobinostat is an approved drug for the treatment of lymphoma and multiple myeloma and a number of HDAC inhibitors are in clinical trials for the treatment of various malignancies [106].”
BackgroundFreese, K., Seitz, T., Dietrich, P., Lee, S. M. L., Thasler, W. E., Bosserhoff, A., & Hellerbrand, C. (2019) · Cancers · doi:10.3390/cancers11101587 · Cited by 123
“Among these, histone deacetylases (HDACs) have been shown to play a key role in different hallmarks of cancer including resistance to apoptosis and chemotherapy resistance [4,5].”
BackgroundThe application of histone deacetylases inhibitors in glioblastoma
Chen, R., Zhang, M., Zhou, Y., Guo, W., Yi, M., Zhang, Z., Ding, Y., & Wang, Y. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01643-6 · Cited by 133
Vorinostat (SAHA) and Breast Cancer: An Overview
Wawruszak, A., Borkiewicz, L., Okoń, E., Kukuła‐Koch, W., Afshan, S., & Hałasa, M. (2021) · Cancers · doi:10.3390/cancers13184700 · Cited by 132
“The HDAC catalytic activity inhibition by SAHA is based on its binding to the zinc ion located in the enzyme catalytic domain [58,94].”
BackgroundMultitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Maramai, S., Benchekroun, M., Gabr, M. T., & Yahiaoui, S. (2020) · BioMed Research International · doi:10.1155/2020/5120230 · Cited by 121
Blueprint for cancer research: Critical gaps and opportunities
Elmore, L. W., Greer, S. F., Daniels, E. C., Saxe, C. C., Melner, M. H., Krawiec, G. M., Cance, W. G., & Phelps, W. C. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21652 · Cited by 157
Liu, J., He, D., Cheng, L., Huang, C., Zhang, Y., Rao, X., Kong, Y., Liu, J., Zhang, Z., Liu, J., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1270-z · Cited by 125
“Indeed, HDAC inhibitors vorinostat (SAHA), belinostat and romidepsin have been approved for T-cell lymphoma treatment and panobinostat (LBH589) for multiple myeloma treatment [33].”
BackgroundSteelant, B., Wawrzyniak, P., Martens, K., Jonckheere, A., Pugin, B., Schrijvers, R., Bullens, D. M. A., Vanoirbeek, J., Krawczyk, K. T., Dreher, A., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2019.04.027 · Cited by 123
Jang, Y.-G., Hwang, K., & Choi, K. (2018) · Nutrients · doi:10.3390/nu10111784 · Cited by 114
“On the other hand, SAHA can have anti-cancer efficacies by inhibiting HDACs and upregulating p53 [50].”
BackgroundPatnaik, S., & Anupriya (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00588 · Cited by 109
Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications
Sher, G., Salman, N. A., Khan, A. Q., Prabhu, K. S., Raza, A., Kuliński, M., Dermime, S., Haris, M., Junejo, K., & Shahab Uddin, M. S. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.009 · Cited by 124
Targeting the acetylation signaling pathway in cancer therapy
Dang, F., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.001 · Cited by 109
Bridging the molecular and biological functions of the oxysterol-binding protein family
Pietrangelo, A., & Ridgway, N. D. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2795-y · Cited by 121
“2.4) [39, 40], which would potentially restrict SREBP2 activation and subsequent HDAC5 expression.”
BackgroundInfluentialCollins, D. M., Conlon, N. T., Kannan, S., Verma, C. S., Eli, L. D., Lalani, A. S., & Crown, J. P. (2019) · Cancers · doi:10.3390/cancers11060737 · Cited by 125
“HDAC inhibitors have multiple effects on cancer cells: cell cycle arrest, differentiation, and cell death; reduction of angiogenesis; and impact on the immune response [123].”
Thakur, A., Tawa, G. J., Henderson, M. J., Danchik, C., Liu, S., Shah, P., Wang, A. Q., Dunn, G., Kabir, M., Padilha, E. C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00193 · Cited by 112
Slaughter, M. J., Shanle, E. K., Khan, A., Chua, K. F., Hong, T., Boxer, L. D., Allis, C. D., Josefowicz, S. Z., Garcia, B. A., Rothbart, S. B., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108638 · Cited by 109
“To identify the effects of HDAC inhibition on histone acetylation, we performed mass spectrometry on histone proteins extracted from HeLa cells with or without treatment with NaBut, a class I/II HDACi (Eckschlager et al., 2017) (Figure 1A).”
MethodQue, Y., Zhang, X.-L., Liu, Z.-X., Zhao, J.-J., Pan, Q.-Z., Wen, X.-Z., Xiao, W., Xu, B.-S., Hong, D.-C., Guo, T.-H., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001696 · Cited by 100
“Figure 1 Gene amplification patterns of drug-target genes.”
Molecular Targets of Natural Compounds with Anti-Cancer Properties
Kubczak, M., Szustka, A., & Rogalińska, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413659 · Cited by 122
Decaesteker, B., Denecker, G., Neste, C. V., Dolman, M. E. M., Loocke, W. V., Gartlgruber, M., Nunes, C., Vloed, F. D., Depuydt, P., Verboom, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06699-9 · Cited by 115
Lauria, A., Monica, G. L., Bono, A., & Martorana, A. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113555 · Cited by 105
Zhai, T., Shizhen, L., Hu, W., Li, D., & Leng, S. (2018) · Nutrients · doi:10.3390/nu10070813 · Cited by 103
“, acetylation of histones H3 and H4) leads to chromatin modeling, which alters gene transcription (including for several anti-oncogenes and DNA repair genes) [107].”
BackgroundThe Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
Loo Yau, H., Ettayebi, I., & De Carvalho, D. D. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.006 · Cited by 96
Bora-Singhal, N., Mohankumar, D., Saha, B., Colin, C., Lee, J. Y., Martin, M. W., Zheng, X., Coppola, D., & Chellappan, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-61295-6 · Cited by 99
Hosseinzadeh, P., Watson, P. R., Craven, T. W., Li, X., Rettie, S., Pardo-Avila, F., Bera, A. K., Mulligan, V. K., Lu, P., Ford, A. S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23609-8 · Cited by 106
New tendencies in non-surgical periodontal therapy
Haas, A. N., Furlaneto, F. A. C., Gaio, E. J., Gomes, S. C., Palioto, D. B., CASTILHO, R. M., Sanz, M., & Messora, M. R. (2021) · Brazilian Oral Research · doi:10.1590/1807-3107bor-2021.vol35.0095 · Cited by 123
Causal identification of single-cell experimental perturbation effects with CINEMA-OT
Dong, M., Wang, B., Wei, J., de O. Fonseca, A. H., Perry, C. J., Frey, A., Ouerghi, F., Foxman, E. F., Ishizuka, J. J., Dhodapkar, R. M., et al. (2023) · Nature Methods · doi:10.1038/s41592-023-02040-5 · Cited by 94
“HDAC inhibitors act as antitumoral agents through antagonizing the pro-transcriptional effects of histone acetylation and silencing the expression of oncogenic factors through chromatin remodeling [35].”
BackgroundBisserier, M., Mathiyalagan, P., Zhang, S., Elmastour, F., Dorfmüller, P., Humbert, M. J. C., David, G., Tarzami, S. T., Weber, T., Perros, F., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.047978 · Cited by 100
Rossaert, E., Pollari, E., Jaspers, T., Van Helleputte, L., Jarpe, M., Van Damme, P., De Bock, K., Moisse, M., & Van Den Bosch, L. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0750-2 · Cited by 93
“HDACs are druggable targets and compounds that inhibit this class of enzymes are used to treat several forms of cancer [24].”
BackgroundA view on multi-action Pt(IV) antitumor prodrugs
Ravera, M., Gabano, E., McGlinchey, M. J., & Osella, D. (2019) · Inorganica Chimica Acta · doi:10.1016/j.ica.2019.04.025 · Cited by 99
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
“VPA is an HDAC inhibitor, and histone deacetylation is associated with gene silencing (507).”
BackgroundOvarian cancer: epigenetics, drug resistance, and progression
Xie, W., Sun, H., Li, X., Lin, F., Wang, Z., & Wang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02136-y · Cited by 107
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
“Currently, several HDACIs are approved for treatment of human malignancies (Eckschlager et al., 2017).”
BackgroundEpigenetic alterations and advancement of treatment in peripheral T-cell lymphoma
Zhang, P., & Zhang, M. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00962-x · Cited by 101
“Histone acetyltransferases (HATs) and histone deacetylases (HDACs) balance each other in the acetylation and deacetylation of histones and play an important role in chromosome structural modification and the regulation of gene expression [15, 16].”
Backgroundp53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102415 · Cited by 85
“Moreover, patients experienced considerable non-selective off-target effects ranging from negligible (such as diarrhea, anorexia, dehydration) to serious (myelosuppression, thrombocytopenia, and cardiotoxicity) outcomes [75,84,97,98].”
BackgroundHsieh, W., Sutter, B. M., Ruess, H., Barnes, S. D., Malladi, V. S., & Tu, B. P. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.015 · Cited by 99
Prognostic and Predictive Epigenetic Biomarkers in Oncology
Kaminska, K. H., Nalejska, E., Kubiak, M., Wojtysiak, J., Żołna, Ł., Kowalewski, J., & Lewandowska, M. A. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0371-7 · Cited by 97
Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents
Ediriweera, M. K., Tennekoon, K. H., & Samarakoon, S. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.02.003 · Cited by 98
Shen, S., Hadley, M. M., Ustinova, K., Pavlíček, J., Knox, T. J., Noonepalle, S. K. R., Tavares, M. T., Zimprich, C., Zhang, G., Robers, M. B., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00946 · Cited by 86
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Ugurel, S., Spassova, I., Wohlfarth, J., Drusio, C., Cherouny, A., Melior, A., Sucker, A., Zimmer, L., Ritter, C., Schadendorf, D., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02341-9 · Cited by 84
Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
Rana, Z., Diermeier, S. D., Hanif, M., & Rosengren, R. J. (2020) · Biomedicines · doi:10.3390/biomedicines8020022 · Cited by 89
“The five classes of HDAC inhibitors include hydroxamic acids, cyclic tetrapeptides, short chain carboxylic acids, benzamides and keto-derivatives [56].”
BackgroundOliveira, T. G., Hermann, E. R., Lin, D., Chowanadisai, W., Hull, E. E., & Montgomery, M. R. (2021) · Redox Biology · doi:10.1016/j.redox.2021.102149 · Cited by 88
Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors
Daskalakis, M., Brocks, D., Sheng, Y.-H., Islam, S., Ressnerova, A., Assenov, Y., Milde, T., Oehme, I., Witt, O., Goyal, A., et al. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442623 · Cited by 93
“Extrinsic as well as intrinsic apoptotic pathways are triggered by HDAC inhibition [54].”
BackgroundInfluentialEpigenetic regulation of cancer stem cell formation and maintenance
French, R., & Pauklin, S. (2020) · International Journal of Cancer · doi:10.1002/ijc.33398 · Cited by 93
“various malignancies either alone or in combination with other therapeutics.(156) Despite promising anticancer effects, results have been mixed and in some cases accompanied by substantial toxicity.”
BackgroundTargeting FoxO transcription factors with HDAC inhibitors for the treatment of osteoarthritis
Ohzono, H., Hu, Y., Nagira, K., Kanaya, H., Okubo, N., Olmer, M., Gotoh, M., Kurakazu, I., Akasaki, Y., Kawata, M., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2021-221269 · Cited by 92
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
Bahl, S., & Seto, E. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03599-4 · Cited by 82
Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy
Manzotti, G., Ciarrocchi, A., & Sancisi, V. (2019) · Cancers · doi:10.3390/cancers11030304 · Cited by 91
Current and emerging therapeutic approaches to pulmonary hypertension
Bisserier, M., Pradhan, N. M., & Hadri, L. (2020) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm.2020.02.597 · Cited by 92
“For example, SAHA (also known as Vorinostat) has been approved for the treatment of cutaneous T-cell Lymphoma (CTCL) (Eckschlager et al., 2017).”
BackgroundInfluentialTargeting epigenetic regulators for inflammation: Mechanisms and intervention therapy
Zhang, S., Meng, Y., Zhou, L., Qiu, L., Wang, H., Su, D., Zhang, B., Chan, K. M., & Han, J. (2022) · MedComm · doi:10.1002/mco2.173 · Cited by 93
DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses
Dan, H., Zhang, S., Zhou, Y., & Guan, Q. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s217767 · Cited by 86
“cycle arrest, differentiation and cell death in cancer cells, reduce angiogenesis, and modulate the immune response.(122) The activity of HDACs can affect the expression of MHC (major histocompatibility complex) and co-stimulatory molecules.”
BackgroundSmall Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy
Wu, D., Qiu, Y., Jiao, Y., Qiu, Z., & Liu, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.560487 · Cited by 79
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
